Sugi Predict

Sugi Predict / Compounds / SCHEMBL1146899

SCHEMBL1146899

SCHEMBL1146899

Cc1sc(N2CCN(C(=O)OC(C)(C)C)CC2)nc1-c1ccc(C(=O)O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CKS1B P61024 2/20 0.50
▸ SKP1 P63208 2/20 0.50
▸ SKP2 Q13309 2/20 0.50
▸ RARA P10276 1/20 0.46
▸ RARB P10826 1/20 0.46
▸ RARG P13631 1/20 0.46
▸ HDAC4 P56524 1/20 0.45
▸ GBA1 P04062 2/20 0.45
▸ AR P10275 1/20 0.45
▸ PPARG P37231 1/20 0.44
▸ PIK3CA P42336 1/20 0.42
▸ TBK1 Q9UHD2 1/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ GPR119 Q8TDV5 4/20 0.41
▸ GRIA1 P42261 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27711575 0.90 CKS1B (0.61) CKS1BSKP1SKP2GBA1AR
SCHEMBL1146996 0.90 CKS1B (0.46) CKS1BSKP1SKP2HDAC4AR
SCHEMBL16075325 0.86 CKS1B (0.47) CKS1BSKP1SKP2HDAC4GBA1
SCHEMBL1873626 0.85 RARA (0.52) RARARARBRARGARMEN1
SCHEMBL1146780 0.82 RARA (0.53) RARARARBRARGARMEN1
Hydrochloric Acid SCHEMBL1169985 0.81 RARA (0.52) RARARARBRARGARMEN1
SCHEMBL9909667 0.81 ALDH1A1 (0.55) RARARARBRARGARMEN1
SCHEMBL1473079 0.80 MAPT (0.58) CKS1BSKP1SKP2GBA1MEN1
SCHEMBL19056939 0.79 CKS1B (0.44) CKS1BSKP1SKP2GBA1PPARG
SCHEMBL1146444 0.78 RARA (0.52) RARARARBRARGARMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378209-B2 Protease inhibitors MEDIVIR AB (SE) 2025-08-05 — — US disclosed
US-20220332690-A1 PROTEASE INHIBITORS MEDIVIR AB (SE) 2022-10-20 — — US disclosed
US-11312693-B2 Protease inhibitors MEDIVIR AB (SE) 2022-04-26 — — US disclosed
US-20210017140-A1 PROTEASE INHIBITORS MEDIVIR AB (SE) 2021-01-21 — — US disclosed
US-10723709-B2 Protease inhibitors MEDIVIR AB (SE) 2020-07-28 — — US disclosed
US-10329266-B2 Protease inhibitors MEDIVIR AB (SE) 2019-06-25 — — US disclosed
US-20180327371-A1 PROTEASE INHIBITORS MEDIVIR AB (SE) 2018-11-15 — — US disclosed
US-20170334867-A1 PROTEASE INHIBITORS MEDIVIR AB (SE) 2017-11-23 — — US disclosed
US-20170334867-A1 PROTEASE INHIBITORS MEDIVIR AB (SE) 2017-11-23 — — US disclosed
US-20170166538-A1 PROTEASE INHIBITORS MEDIVIR AB (SE) 2017-06-15 — — US disclosed
US-20090023748-A1 Cysteine Protease Inhibitors MEDIVIR AB (SE) 2009-01-22 — — US disclosed
US-20090023748-A1 Cysteine Protease Inhibitors MEDIVIR AB (SE) 2009-01-22 — — US disclosed
WO-2009000877-A1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2008-12-31 — — WO disclosed
WO-2009000877-A1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2008-12-31 — — WO disclosed
US-20080234260-A1 Cysteine Protease inhibitors MEDIVIR AB (SE) 2008-09-25 — — US disclosed
WO-2008114054-A1 PROTEASE INHIBITORS MEDIVIR AB (SE) 2008-09-25 — — WO disclosed
WO-2005066180-A9 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2008-09-25 — — WO disclosed
WO-2007006714-A1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2007-01-18 — — WO disclosed
EP-1701960-A1 CYSTEINE PROTEASE INHIBITORS Medivir Aktiebolag (SE) 2006-09-20 — — EP disclosed
WO-2005066180-A1 CYSTEINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2005-07-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10723709-B2 Protease inhibitors CTSK, CTSF, CTSS CKS1B 410/4885SKP1 845/4885SKP2 794/4885
US-11312693-B2 Protease inhibitors CTSK, CTSF, CTSS CKS1B 410/4885SKP1 845/4885SKP2 794/4885
US-20080234260-A1 Cysteine Protease inhibitors CTSS, CTSZ, CTSK CKS1B 64/4885SKP1 590/4885SKP2 253/4885
US-10329266-B2 Protease inhibitors CTSK, CTSF, CTSS CKS1B 410/4885SKP1 845/4885SKP2 794/4885
US-20090023748-A1 Cysteine Protease Inhibitors CTSK, CTSL, CTSV CKS1B 133/4885SKP1 108/4885SKP2 18/4885
US-12378209-B2 Protease inhibitors MMP26, CTSK, TMPRSS6 CKS1B 399/4885SKP1 933/4885SKP2 805/4885
US-20170334867-A1 PROTEASE INHIBITORS CTSK, MMP26, MMP3 CKS1B 651/4885SKP1 1347/4885SKP2 726/4885
US-20210017140-A1 PROTEASE INHIBITORS CTSK, CTSF, CTSS CKS1B 410/4885SKP1 845/4885SKP2 794/4885
US-20180327371-A1 PROTEASE INHIBITORS CTSK, CTSF, CTSS CKS1B 410/4885SKP1 845/4885SKP2 794/4885
US-20170166538-A1 PROTEASE INHIBITORS MMP8, CTSK, CTSS CKS1B 305/4885SKP1 839/4885SKP2 1099/4885
US-20220332690-A1 PROTEASE INHIBITORS MMP26, CTSK, TMPRSS6 CKS1B 399/4885SKP1 933/4885SKP2 805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.